Description
Coronado Biosciences, Inc. is a biopharmaceutical company. The Company is involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer: CNDO-201 and CNDO-109. The Company is engaged in planning, identifying, evaluating and in-license, acquire and invest in pharmaceutical and biotechnology products, technologies and companies. CNDO-201 is a biologic comprising the microscopic eggs of the porcine whipworm used in treatment of autoimmune diseases, such as crohn’s disease, ulcerative colitis, multiple sclerosis, autism, psoriasis and Type 1 diabetes. CNDO-109 is a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells that cause hematologic malignancies, including myeloid leukemia and multiple myeloma, as well as breast, prostate and ovarian cancers. The Company also develops a portfolio of human immuno-oncology targeted antibodies through its subsidiary, Checkpoint Therapeutics, Inc.
Address
24 New England Executive Park
BURLINGTON, MA 01803
United States
BURLINGTON, MA 01803
United States
Website
coronadobiosciences.comKey stats and ratios
| Q4 (Dec '14) | 2014 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -16.80% | -21.47% |
| Return on average equity | -21.31% | -26.86% |
| Employees | 14 |
No comments:
Post a Comment